# Aurobindo Pharma USA Inc, East Windsor, NJ – FDA Inspections

Source: https://www.keypedia.com/companies/aurobindo-pharma-usa-inc/a8dbf5ca-1af1-432a-85b6-5a0c7499eaa5

> Inspection records and compliance data for Aurobindo Pharma USA Inc in East Windsor, New Jersey. 5 FDA inspections on record (1 OAI), last inspected June 04, 2026.

---

## Details

- Name: Aurobindo Pharma USA Inc
- FEI Number: 3008460374
- Address Line 1: 279 Princeton Hightstown Rd
- City: East Windsor
- State: New Jersey
- Zip Code: 08520
- Country Name: United States
- Address: 279 Princeton Hightstown Rd, East Windsor, New Jersey 08520, United States
- Country: United States

## Inspection summary

- FDA inspections: 5 (July 29, 2011 to June 4, 2026)
- Classifications: NAI 2, VAI 1, OAI 1
- Form 483s: 0
- Warning letters: 0
- Most cited issues: Contamination, chemical or physical change, deterioration (1); Failure to develop written procedures (1); Failure to review ADE information (1)

## FDA inspections

- June 4, 2026 — Human Drugs
- [May 15, 2024](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-usa-inc/653906f9-7952-4bff-9baa-c6b093dcc401) — Official Action Indicated (OAI), Human Drugs, Drug Quality Assurance
- December 12, 2014 — No Action Indicated (NAI), Human Drugs, Drug Quality Assurance
- May 30, 2012 — No Action Indicated (NAI), Human Drugs, Bioresearch Monitoring
- [July 29, 2011](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-usa-inc/bacfcc10-9940-4b19-9084-4bb60639c9f3) — Voluntary Action Indicated (VAI), Human Drugs, Bioresearch Monitoring

## Form 483s (3)

- [483 - Aurobindo Pharma USA Inc - 2024-06-15](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/bd6c21d0-cf5a-478a-b0e5-d85571f30522) — June 15, 2024
- [483 - Aurobindo Pharma USA Inc - 2024-05-13](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/23d87088-0c57-415a-b47d-edecbaeb8f2b) — May 13, 2024
- [483 - Aurobindo Pharma USA Inc - 2019-07-19](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/5f846bc0-d7ea-4e9a-9d63-fae85c1032c6) — July 19, 2019

## Related Documents

- FDA Inspection 1316082 - Aurobindo Pharma USA Inc - 2026-06-04 — source: FDA, date: June 4, 2026
- [483 - Aurobindo Pharma USA Inc - 2024-06-15](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/bd6c21d0-cf5a-478a-b0e5-d85571f30522) — source: FDA, date: June 15, 2024
- [FDA Inspection 1238442 - Aurobindo Pharma USA Inc - 2024-05-15](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-usa-inc/653906f9-7952-4bff-9baa-c6b093dcc401) — classification: Official Action Indicated (OAI), source: FDA, date: May 15, 2024
- [483 - Aurobindo Pharma USA Inc - 2024-05-13](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/23d87088-0c57-415a-b47d-edecbaeb8f2b) — source: FDA, date: May 13, 2024
- [483 - Aurobindo Pharma USA Inc - 2019-07-19](https://www.keypedia.com/records/483/aurobindo-pharma-usa-inc/5f846bc0-d7ea-4e9a-9d63-fae85c1032c6) — source: FDA, date: July 19, 2019
- FDA Inspection 908515 - Aurobindo Pharma USA Inc - 2014-12-12 — classification: No Action Indicated (NAI), source: FDA, date: December 12, 2014
- FDA Inspection 908515 - Aurobindo Pharma USA Inc - 2014-12-12 — classification: No Action Indicated (NAI), source: FDA, date: December 12, 2014
- FDA Inspection 783745 - Aurobindo Pharma USA Inc - 2012-05-30 — classification: No Action Indicated (NAI), source: FDA, date: May 30, 2012
- [FDA Inspection 736360 - Aurobindo Pharma USA Inc - 2011-07-29](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-usa-inc/bacfcc10-9940-4b19-9084-4bb60639c9f3) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 29, 2011
- FDA Inspection 736360 - Aurobindo Pharma USA Inc - 2011-07-29 — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 29, 2011

## Related Companies

- [Inopak Ltd](https://www.keypedia.com/companies/inopak-ltd/0e7c501d-9636-4cc2-b8dc-f2a1cb0c3f44)
- [Dr. Reddy's Laboratories, Inc.](https://www.keypedia.com/companies/dr-reddys-laboratories-inc/ec3847d0-42b8-478b-bb7e-5e986389f184)
- [Vantage Specialty Ingredients](https://www.keypedia.com/companies/vantage-specialty-ingredients/61ceb95e-844d-4b4b-a2e9-cf927d214d27)
- [Nationwide Laboratories, LLC](https://www.keypedia.com/companies/nationwide-laboratories-llc/e5dccf31-f7a6-4a51-9f59-7e2929127933)
- [NuSil Technology LLC](https://www.keypedia.com/companies/nusil-technology-llc/ef176ca7-d941-4939-89a4-be78633f5cb4)
- [John D. Gabriel, MD](https://www.keypedia.com/companies/john-d-gabriel-md/6c8dab33-f0fe-48ec-8b27-7c62dededa1f)
- [Rpk Pharmaceuticals Inc](https://www.keypedia.com/companies/rpk-pharmaceuticals-inc/4fcc57aa-1dbd-44d8-859b-3754c50751af)
- [Corden Pharma Boulder, Inc.](https://www.keypedia.com/companies/corden-pharma-boulder-inc/ac780a14-1ead-48c8-8376-cb62f7114aec)
- [West Coast Cosmetics Inc](https://www.keypedia.com/companies/west-coast-cosmetics-inc/6d3129c0-b7de-4b7c-b7ee-f115624a9b8e)
- [Joseph L. Lillo, D.O.](https://www.keypedia.com/companies/joseph-l-lillo-do/1ea0d267-f3a4-4b8f-9611-61ba95abc6b1)

## Related Officers

- [company_representative](https://www.keypedia.com/people/maria-t-bradfish/3e002ea4-0b63-45b8-9ded-fb31909dc059)
- [Michael Todd](https://www.keypedia.com/people/michael-todd/d582fb48-2907-430c-b265-ee5eb6770047)
- [Drug Investigator](https://www.keypedia.com/people/samir-c-gala/904c34ee-013d-4663-a87a-9cbdbcf2b40e)
